Protein transfer enhances cellular immune responses to DNA vaccination against SARS-CoV.
Identifieur interne : 001811 ( PubMed/Checkpoint ); précédent : 001810; suivant : 001812Protein transfer enhances cellular immune responses to DNA vaccination against SARS-CoV.
Auteurs : Youmin Kang [République populaire de Chine] ; Aoshuang Chen ; Bin Wang ; Guoxing ZhengSource :
- Viral immunology [ 1557-8976 ] ; 2009.
Descripteurs français
- KwdFr :
- Acide palmitique (administration et posologie), Activation des lymphocytes, Adjuvants immunologiques (administration et posologie), Animaux, Anticorps antiviraux (biosynthèse), Cellules cultivées (immunologie), Cellules présentatrices d'antigène (immunologie), Cytotoxicité immunologique, Fragments Fc des immunoglobulines (immunologie), Humains, Hypersensibilité retardée (immunologie), Immunité cellulaire, Immunoconjugués (administration et posologie), Immunoconjugués (immunologie), Immunoglobuline G (immunologie), Ligand de 4-1BB (administration et posologie), Ligand de 4-1BB (immunologie), Lymphocytes T cytotoxiques (immunologie), Protéine A staphylococcique (administration et posologie), Protéine A staphylococcique (immunologie), Protéines de fusion recombinantes (immunologie), Protéines nucléocapside (immunologie), Souris, Souris de lignée BALB C, Souris de lignée C57BL, Syndrome respiratoire aigu sévère (), Vaccination, Vaccins à ADN (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Acide palmitique, Adjuvants immunologiques, Immunoconjugués, Ligand de 4-1BB, Protéine A staphylococcique.
- biosynthèse : Anticorps antiviraux.
- immunologie : Cellules cultivées, Cellules présentatrices d'antigène, Fragments Fc des immunoglobulines, Hypersensibilité retardée, Immunoconjugués, Immunoglobuline G, Ligand de 4-1BB, Lymphocytes T cytotoxiques, Protéine A staphylococcique, Protéines de fusion recombinantes, Protéines nucléocapside, Vaccins à ADN, Virus du SRAS.
- Activation des lymphocytes, Animaux, Cytotoxicité immunologique, Humains, Immunité cellulaire, Souris, Souris de lignée BALB C, Souris de lignée C57BL, Syndrome respiratoire aigu sévère, Vaccination.
English descriptors
- KwdEn :
- 4-1BB Ligand (administration & dosage), 4-1BB Ligand (immunology), Adjuvants, Immunologic (administration & dosage), Animals, Antibodies, Viral (biosynthesis), Antigen-Presenting Cells (immunology), Cells, Cultured (immunology), Cytotoxicity, Immunologic, Humans, Hypersensitivity, Delayed (immunology), Immunity, Cellular, Immunoconjugates (administration & dosage), Immunoconjugates (immunology), Immunoglobulin Fc Fragments (immunology), Immunoglobulin G (immunology), Lymphocyte Activation, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Nucleocapsid Proteins (immunology), Palmitic Acid (administration & dosage), Recombinant Fusion Proteins (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Staphylococcal Protein A (administration & dosage), Staphylococcal Protein A (immunology), T-Lymphocytes, Cytotoxic (immunology), Vaccination, Vaccines, DNA (immunology).
- MESH :
- chemical , administration & dosage : 4-1BB Ligand, Adjuvants, Immunologic, Immunoconjugates, Palmitic Acid, Staphylococcal Protein A.
- chemical , biosynthesis : Antibodies, Viral.
- chemical , immunology : 4-1BB Ligand, Immunoconjugates, Immunoglobulin Fc Fragments, Immunoglobulin G, Nucleocapsid Proteins, Recombinant Fusion Proteins, Staphylococcal Protein A, Vaccines, DNA.
- immunology : Antigen-Presenting Cells, Cells, Cultured, Hypersensitivity, Delayed, SARS Virus, T-Lymphocytes, Cytotoxic.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Cytotoxicity, Immunologic, Humans, Immunity, Cellular, Lymphocyte Activation, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Vaccination.
Abstract
The current DNA vaccine formulations are not optimal for stimulation of CD8(+) T cells, which are required for clearing virally-infected cells. Here we show that CD8(+) T cell-stimulating activity can be effectively augmented by combining DNA vaccination with protein transfer. C57BL/6 mice were injected intramuscularly with an anti-SARS-CoV DNA vaccine admixed with a lipid-derived conjugate of 4-1BBL, a potential CD8(+) T-cell co-stimulator. The inclusion of the lipidated co-stimulator greatly enhanced cellular immune responses, especially the CTL response, induced by the DNA vaccine. The adjuvant effect of 4-1BBL was lipidation-dependent, indicating that it functions as a cell membrane-anchored co-stimulator. Results of our study suggest, for the first time, that muscle cells may be modified in situ, at the DNA injection site, into APC-like cells to allow direct priming of CD8(+) T cells and thereby improve the efficacy of DNA vaccines.
DOI: 10.1089/vim.2009.0048
PubMed: 19951178
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19951178Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protein transfer enhances cellular immune responses to DNA vaccination against SARS-CoV.</title><author><name sortKey="Kang, Youmin" sort="Kang, Youmin" uniqKey="Kang Y" first="Youmin" last="Kang">Youmin Kang</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Chen, Aoshuang" sort="Chen, Aoshuang" uniqKey="Chen A" first="Aoshuang" last="Chen">Aoshuang Chen</name></author><author><name sortKey="Wang, Bin" sort="Wang, Bin" uniqKey="Wang B" first="Bin" last="Wang">Bin Wang</name></author><author><name sortKey="Zheng, Guoxing" sort="Zheng, Guoxing" uniqKey="Zheng G" first="Guoxing" last="Zheng">Guoxing Zheng</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19951178</idno><idno type="pmid">19951178</idno><idno type="doi">10.1089/vim.2009.0048</idno><idno type="wicri:Area/PubMed/Corpus">001786</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001786</idno><idno type="wicri:Area/PubMed/Curation">001786</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001786</idno><idno type="wicri:Area/PubMed/Checkpoint">001811</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001811</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Protein transfer enhances cellular immune responses to DNA vaccination against SARS-CoV.</title><author><name sortKey="Kang, Youmin" sort="Kang, Youmin" uniqKey="Kang Y" first="Youmin" last="Kang">Youmin Kang</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Chen, Aoshuang" sort="Chen, Aoshuang" uniqKey="Chen A" first="Aoshuang" last="Chen">Aoshuang Chen</name></author><author><name sortKey="Wang, Bin" sort="Wang, Bin" uniqKey="Wang B" first="Bin" last="Wang">Bin Wang</name></author><author><name sortKey="Zheng, Guoxing" sort="Zheng, Guoxing" uniqKey="Zheng G" first="Guoxing" last="Zheng">Guoxing Zheng</name></author></analytic><series><title level="j">Viral immunology</title><idno type="eISSN">1557-8976</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>4-1BB Ligand (administration & dosage)</term><term>4-1BB Ligand (immunology)</term><term>Adjuvants, Immunologic (administration & dosage)</term><term>Animals</term><term>Antibodies, Viral (biosynthesis)</term><term>Antigen-Presenting Cells (immunology)</term><term>Cells, Cultured (immunology)</term><term>Cytotoxicity, Immunologic</term><term>Humans</term><term>Hypersensitivity, Delayed (immunology)</term><term>Immunity, Cellular</term><term>Immunoconjugates (administration & dosage)</term><term>Immunoconjugates (immunology)</term><term>Immunoglobulin Fc Fragments (immunology)</term><term>Immunoglobulin G (immunology)</term><term>Lymphocyte Activation</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mice, Inbred C57BL</term><term>Nucleocapsid Proteins (immunology)</term><term>Palmitic Acid (administration & dosage)</term><term>Recombinant Fusion Proteins (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Staphylococcal Protein A (administration & dosage)</term><term>Staphylococcal Protein A (immunology)</term><term>T-Lymphocytes, Cytotoxic (immunology)</term><term>Vaccination</term><term>Vaccines, DNA (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acide palmitique (administration et posologie)</term><term>Activation des lymphocytes</term><term>Adjuvants immunologiques (administration et posologie)</term><term>Animaux</term><term>Anticorps antiviraux (biosynthèse)</term><term>Cellules cultivées (immunologie)</term><term>Cellules présentatrices d'antigène (immunologie)</term><term>Cytotoxicité immunologique</term><term>Fragments Fc des immunoglobulines (immunologie)</term><term>Humains</term><term>Hypersensibilité retardée (immunologie)</term><term>Immunité cellulaire</term><term>Immunoconjugués (administration et posologie)</term><term>Immunoconjugués (immunologie)</term><term>Immunoglobuline G (immunologie)</term><term>Ligand de 4-1BB (administration et posologie)</term><term>Ligand de 4-1BB (immunologie)</term><term>Lymphocytes T cytotoxiques (immunologie)</term><term>Protéine A staphylococcique (administration et posologie)</term><term>Protéine A staphylococcique (immunologie)</term><term>Protéines de fusion recombinantes (immunologie)</term><term>Protéines nucléocapside (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Souris de lignée C57BL</term><term>Syndrome respiratoire aigu sévère ()</term><term>Vaccination</term><term>Vaccins à ADN (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>4-1BB Ligand</term><term>Adjuvants, Immunologic</term><term>Immunoconjugates</term><term>Palmitic Acid</term><term>Staphylococcal Protein A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>4-1BB Ligand</term><term>Immunoconjugates</term><term>Immunoglobulin Fc Fragments</term><term>Immunoglobulin G</term><term>Nucleocapsid Proteins</term><term>Recombinant Fusion Proteins</term><term>Staphylococcal Protein A</term><term>Vaccines, DNA</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Acide palmitique</term><term>Adjuvants immunologiques</term><term>Immunoconjugués</term><term>Ligand de 4-1BB</term><term>Protéine A staphylococcique</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cellules cultivées</term><term>Cellules présentatrices d'antigène</term><term>Fragments Fc des immunoglobulines</term><term>Hypersensibilité retardée</term><term>Immunoconjugués</term><term>Immunoglobuline G</term><term>Ligand de 4-1BB</term><term>Lymphocytes T cytotoxiques</term><term>Protéine A staphylococcique</term><term>Protéines de fusion recombinantes</term><term>Protéines nucléocapside</term><term>Vaccins à ADN</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antigen-Presenting Cells</term><term>Cells, Cultured</term><term>Hypersensitivity, Delayed</term><term>SARS Virus</term><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cytotoxicity, Immunologic</term><term>Humans</term><term>Immunity, Cellular</term><term>Lymphocyte Activation</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mice, Inbred C57BL</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activation des lymphocytes</term><term>Animaux</term><term>Cytotoxicité immunologique</term><term>Humains</term><term>Immunité cellulaire</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Souris de lignée C57BL</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The current DNA vaccine formulations are not optimal for stimulation of CD8(+) T cells, which are required for clearing virally-infected cells. Here we show that CD8(+) T cell-stimulating activity can be effectively augmented by combining DNA vaccination with protein transfer. C57BL/6 mice were injected intramuscularly with an anti-SARS-CoV DNA vaccine admixed with a lipid-derived conjugate of 4-1BBL, a potential CD8(+) T-cell co-stimulator. The inclusion of the lipidated co-stimulator greatly enhanced cellular immune responses, especially the CTL response, induced by the DNA vaccine. The adjuvant effect of 4-1BBL was lipidation-dependent, indicating that it functions as a cell membrane-anchored co-stimulator. Results of our study suggest, for the first time, that muscle cells may be modified in situ, at the DNA injection site, into APC-like cells to allow direct priming of CD8(+) T cells and thereby improve the efficacy of DNA vaccines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19951178</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-8976</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Viral immunology</Title><ISOAbbreviation>Viral Immunol.</ISOAbbreviation></Journal><ArticleTitle>Protein transfer enhances cellular immune responses to DNA vaccination against SARS-CoV.</ArticleTitle><Pagination><MedlinePgn>417-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/vim.2009.0048</ELocationID><Abstract><AbstractText>The current DNA vaccine formulations are not optimal for stimulation of CD8(+) T cells, which are required for clearing virally-infected cells. Here we show that CD8(+) T cell-stimulating activity can be effectively augmented by combining DNA vaccination with protein transfer. C57BL/6 mice were injected intramuscularly with an anti-SARS-CoV DNA vaccine admixed with a lipid-derived conjugate of 4-1BBL, a potential CD8(+) T-cell co-stimulator. The inclusion of the lipidated co-stimulator greatly enhanced cellular immune responses, especially the CTL response, induced by the DNA vaccine. The adjuvant effect of 4-1BBL was lipidation-dependent, indicating that it functions as a cell membrane-anchored co-stimulator. Results of our study suggest, for the first time, that muscle cells may be modified in situ, at the DNA injection site, into APC-like cells to allow direct priming of CD8(+) T cells and thereby improve the efficacy of DNA vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Youmin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Aoshuang</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Guoxing</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Viral Immunol</MedlineTA><NlmUniqueID>8801552</NlmUniqueID><ISSNLinking>0882-8245</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053330">4-1BB Ligand</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018796">Immunoconjugates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007141">Immunoglobulin Fc Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013205">Staphylococcal Protein A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C099602">nucleocapsid protein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>2V16EO95H1</RegistryNumber><NameOfSubstance UI="D019308">Palmitic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053330" MajorTopicYN="N">4-1BB Ligand</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000938" MajorTopicYN="N">Antigen-Presenting Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006968" MajorTopicYN="N">Hypersensitivity, Delayed</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018796" MajorTopicYN="N">Immunoconjugates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007141" MajorTopicYN="N">Immunoglobulin Fc Fragments</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019308" MajorTopicYN="N">Palmitic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013205" MajorTopicYN="N">Staphylococcal Protein A</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19951178</ArticleId><ArticleId IdType="doi">10.1089/vim.2009.0048</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country><settlement><li>Pékin</li></settlement></list><tree><noCountry><name sortKey="Chen, Aoshuang" sort="Chen, Aoshuang" uniqKey="Chen A" first="Aoshuang" last="Chen">Aoshuang Chen</name><name sortKey="Wang, Bin" sort="Wang, Bin" uniqKey="Wang B" first="Bin" last="Wang">Bin Wang</name><name sortKey="Zheng, Guoxing" sort="Zheng, Guoxing" uniqKey="Zheng G" first="Guoxing" last="Zheng">Guoxing Zheng</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Kang, Youmin" sort="Kang, Youmin" uniqKey="Kang Y" first="Youmin" last="Kang">Youmin Kang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001811 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001811 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:19951178
|texte= Protein transfer enhances cellular immune responses to DNA vaccination against SARS-CoV.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19951178" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |